PRiMo: Clinician Training

Using Polygenic Risk Modification to improve breast cancer prevention trial (PRiMo) is a national randomised clinical trial that aims to evaluate the use of a personalised risk assessment for breast and ovarian cancer in clinical practice. Findings from the trial will inform the development of best-practice guidelines for assessing potentially high-risk women and personalising cancer risk management.

This website and workshop have been developed because the use of a personalised risk assessment that includes monogenic, polygenic, clinical and lifestyle factors is a novel element in clinical genetics practice.

Our aims are to:

1. ensure that you are confident with the theoretical underpinnings and practical use of a polygenic risk score (PRS) in personalised risk assessment and;
2. prepare you to return personalised risk assessment results, that include breast and ovarian PRS, and matching risk management strategies.

Completion of this training is required for clinicians to provide results to women participating in the trial.

This training has two parts:  

1. Online learning module with mandatory video presentations and supplementary written information. Completion of the online module should take approximately 1.5-hours. The online module will cover the following topics:
   1. Understanding PRS, breast and ovarian cancer risk and personalised risk assessments
   2. The PRiMo Trial
   3. Communicating personalised risk assessment results

• A virtual workshop that will include role plays and Q&A covering the communication and interpretation of PRS. Completion of the 1.5-hour virtual workshop is mandatory.